The first subject enrolled in the Phase I clinical study of BPI-572270, a broad-spectrum RAS inhibitor developed by Beta Pharmaceutical.

On January 29th, Beta Pharmaceuticals completed the enrollment of the first subject in the Phase I clinical study of BPI-572270 capsules. According to Beta Pharmaceuticals, the full name of the study is "Evaluation of Safety, Tolerability, Pharmacokinetics, and Efficacy of BPI-572270 Capsules in Patients with Late-Stage Solid Tumors with RAS Mutation: Phase I/II Clinical Study," with Professor Song Zhenbo from Zhejiang Cancer Hospital as the principal investigator.